natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to any of claims 1 to 7, wherein said composition preferably is a vaccine, suitable for intravenous, intra-arterial, intraperitoneal, intramuscular, intradermal, intratumoral, oral, dermal, nasal, buccal, rectal, vaginal, topical administration, or suitable for inhalation. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva namijenjen intravenoznoj, intra-arterijskoj, intraperitonalnoj, intramuskularnoj, intradermalnoj, intratumorskoj, oralnoj, dermalnoj, nazalnoj, bukalnoj, rektalnoj, vaginalnoj, inhalacijskoj ili topijskoj primjeni.
which in combination with the base part (2) at least minimally approximately have the desired deformation characteristics at the positions; fitting of the selected inserts (3, 4, 5) in the base part (2) at the aforementioned positions. 
odabir umetaka (3, 4, 5) koji će se koristiti s popisa ili zalihe mogućih umetaka (3, 4, 5), koji u kombinaciji s osnovnim dijelom (2) imaju željene deformacijske karakteristike na tim položajima i kad ta osoba leži bočno na madracu (1), stupanj kompresije u zonama ramena, struka i kukova jednak je navedenim ciljnim vrijednostima;
The antibody or epitope-binding fragment thereof of claim 1, characterized in that said antibody or epitope-binding fragment thereof is capable of killing said CD38+ cell by apoptosis, ADCC, and CDC. 
je navedeno protutijelo sposobno ubiti CD38+ stanicu apoptozom, stanično-posredovanom citotoksičnošću ovisnom o protutijelu (ADCC), i komplementarno ovisnom citotoksičnošću (CDC);
A procedure according to claim 6, characterized in that said coupling is achieved by means of adhesives or flame, or ultrasound or stitching. 
Postupak prema zahtjevu 5, naznačen time što se spajanje postiže pomoću adheziva ili plamena, ili ultrazvukom ili
Example 6: Tablets by granulation process g of donepezil hydrochloride hydrate, 4491 g of macrocrystalline cellulose, 1714 g of lactose monohydrate, 223 g of hydroxypropylcellulose and 750 g of low-substituted hydroxypropylcellulose were homogenised in a high shear mixer. 
Primjer 6: Tablete dobivene postupkom granulacije 279 g donepezil hidroklorid hidrata, 4491 g mikrokristalne celuloze, 1714 g monohidratne laktoze i 223 g hidroksipropilne celuloze i 750 g nisko supstituirane hidroksipropilne celuloze homogenizirano je u sjeckajućem mikseru.
Preferably, the containers according to the present invention are chosen from the group made up of cans, cardboard boxes of the single-serving carton or Tetrapack® type, glass or plastic bottles. 
Ambalažno pakiranje (1) u skladu s bilo kojim od prethodnih zahtjeva, naznačeno time da su navedeni spremnici (2) odabrani iz skupine koja se sastoji od limenki, konzervi, staklenki, kartonskih kutija tetraedarskog tipa ili tetrapaka Đ.
The invention relates to a pharmaceutical composition based on an active principle, such as primarily Sucralfate, for the treatment of disorders related to gastrointestinal irritation such as gastric ulcers, duodenal ulcers, acute gastritis, symptomatic chronic gastritis, gastropathy related to anti-inflammatories, reflux esophagitis, characterized by comprising one or more phospholipids. 
PATENTNI ZAHTJEVI Pr oi Farmaceutska smjesa koja sadrži sukralfat kao djelatnu tvar za liječenje iritabilnih probavnih poremećaja kao što je čir na želucu, čir na dvanaesniku, akutni gastritis, simptomatski kronični gastritis, gastropatija povezana s protuupalnim lijekovima, rTefluksni ezofagitis, naznačena time što sadrži jedan ili više fosfolipida.
The composition of claim 1 or 2, wherein the amino acid is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, threonine, tryptophan, tyrosine and valine. 
Kompozicija sukladno zahtjevu 1 ili 2, pri tome je aminokiselina odabrana iz skupine koja se sastoji od alanina, arginina, asparagina, asparaginske kiseline, cisteina, glutaminske kiseline, glutamina, glicina, histidina, izoleucina, leucina, lizina, metionina, fenilalanina, prolina, pirolizina, selenocisteina, serina, treonina, triptofana, tirozina i valina.
A method of encapsulating at least one agent in silk fibroin, comprising: contacting a silk fibroin solution with an ultrasonication treatment for a period of about 5 seconds to about 60 seconds to initiate gelation, wherein the silk fibroin solution has a pH of 7.5 or higher; and 
Postupak kapsuliranja barem jednog sredstva u fibroin svile, obuhvaća: uvođenje sredst(a)va u otopinu fibroina svile; i dovođenje u doticaj otopine fibroina svile s obradom pomoću ultrazvukom kroz vrijeme od oko 5 sekundi do oko 60 sekundi radi započinjanja geliranja; kako bi se dobilo sredstvo kapsulirano u fibroinu svile.
A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-12, ili njegovu farmaceutski prihvatljivu sol, 1 farmaceutski prihvatljiv nosač.
a plurality of drug positions in each of which the single passageway inlet is aligned with and fluidly connected to a respective one of said drug outlets for guiding an associated drug fluid via a flow path defined by said passageway to said passageway outlet, and 
veći broj pozicija za davanje lijekova u svakom od kojih je jedinstveni dovod (322) prolaza u protočnoj vezi s odgovarajućim od navedenih odvoda (208) za lijekove radi vođenja odgovarajućeg lijeka u obliku tekućine kroz putanju definiranu od strane navedenog prolaza (320; 321) do navedenog odvoda prolaza (324), i
a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase inhibitor, preferably bengamide or a derivative thereof, or a proteosome inhibitor, preferably PS-341, and/or 
inhibitor proteaze, inhibitor metaloproteinaze matriksa, inhibitor aminopeptidaze metionina, poželjno bengamid ili njegov derivat, ili inhibitor proteozoma, poželjno PS-341, i/ili mTOR-inhibitor.
The method as claimed in claim 16, wherein the message controller extracts the MSISDN or equivalent in the original routing query and determines what further information could be obtained in addition to what was requested in the original routing query. 
Postupak prema zahtjevu 10, pri čemu kontroler poruka ekstrahira MSISDN ili njegov ekvivalent iz originalnog upita za dostavljanje informacija o rutiranju i određuje koje se dodatne informacije mogu dobiti u odnosu na one koje su zahtijevane originalnim upitom za dostavljanje informacija o rutiranju.
obtaining the (4S, 6S) enantiomer by selectively precipitating and recovering the camphorsulfonic acid salt thereof (dorzolamide camphorsulfonate) of formula (III) and 
o b) dobivanjem (48, 6S) enantiomera selektivno precipitirajući 1 izolirajući sol kamforsulfonske kiseline (dorzolamid kamforsulfonat) formule (III) u O
The function of the additional components in the melt layer is by way of example to permit the required introduction of energy for melting the melt layer, or to provide partial or homogeneous coloring of the melt layer. 
što je rubna traka napravljena u dva ili više sloja, pri čemu se sloj taljevine dobije (naknadnom) tekućom oblogom koja se učvršćuje umrežavanjem ili sušenjem ili hlađenjem prethodno otopljene osnove polimera sloja taljevine.
adding a composition comprising a reactive molecule selected from the group consisting of water, hydrogen sulfide, and a lower alkyl monohydric alcohol to the composition comprising the active succinimidyl carbonate ester of a water-soluble polyethylene glycol polymer and unreacted disuccinimidyl carbonate, wherein the composition comprising the reactive molecule is added such that substantially all of the unreacted disuccinimidyl carbonate is substantially consumed wherein compositions resulting from step (a) are not isolated prior to conducting step (b). 
dodavanje, prije rekuperacije aktivnog karbonatnog estera vodotopljivog polimera, kompozicije koja sadrži reaktivnu molekulu i koja je izabrana iz grupe koja se sastoji od vode, nižeg alkil monohidroksilnog alkohola, vodikova sulfida i nižeg alkil monobaznog amina, kompoziciji koja sadrži aktivni karbonatni ester vodotopljivog polimera i neizreagirani aktivirani karbonatni reagens, pri čemu se kompozicija koja sadrži reaktivnu molekulu dodaje tako da se potroši više od 50% neizreagiranog aktiviranog karbonatnog reagensa.
It was mixed and separated. 
Tada je bila izmiješana i odvojena.
A multi-specific antibody molecule according to claim 10, wherein the position of the pair of engineered cysteine residues is VH44 and VL100. 
Multispecifična molekula antitijela prema patentnom zahtjevu 10, naznačena time da je pozicija para projektiranih ostataka cisteina VH44 i VL100.
Total number of samples per subject 
(21) Broj predmeta:
a galactomannan at a concentration of 0.1 to 0.4 w/v%; borate at a concentration of 0.4 to 2.0 w/v%; and a sparingly soluble particulate compound, said compound having a solubility in water at 25°C of 0.001 to 0.1 w/v%. 
galaktomanan s koncentracijom od 0,1 do 0,4 % (masa/volumen); borat s koncentracijom od 0,4 do 2,0 % (masa/volumen); i teško topivi spoj lebdećih čestica, gdje navedenom spoju topivost u vodi na 25°C, iznosi od 0,001 do 0,1 % (masa/volumen).
A method of analyzing a biological sample of an organism, the biological sample including DNA originating from normal cells and potentially from cells associated with cancer, wherein at least some of the DNA is cell-free in the biological sample, the method comprising: 
Metoda za analizu uzorka materinske plazme uzetog od trudnice, pri čemu uzorak sadrži fragmente izvanstanične DNK koji potječu iz materinskih stanica i fetalnih stanica, pri čemu se metoda sastoji od:
from about 0.1% to about 2% by weight on a dry weight basis of magnesium stearate. 
od 0,1 do 2 masena postotka na bazi suhe mase magnezijevog stearata;
X-[(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m-Y (S 1) wherein X is H, or an acetyl group or any natural amino acid or sequence of amino acids provided with a free or at least acetyl-derivatized NH2 group; Y is an OH group or an NH2 group or any amino acid or sequence of amino acids with a C-terminal carboxy-amide group; "n" is an integer from 1 to 10 and "m" is an integer from 1 to 3. 
(S 1) naznačena time da X je H, ili acetil grupa ili bilo koja prirodna aminokiselina ili sekvenca aminokiselina koja ima slobodnu ili barem acetil-derivatiziranu NH, skupinu; Y je skupina OH ili NH> skupina; "n" je cijeli broj od 1 do 10 i "m" je cijeli broj od 1 do 3; i pri čemu se aminokiselinska sekvenca molekule izvedene iz peptida bira iz skupine koja se sastoji od:
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell or cell capable of secreting GIP is indicative of the test compound being a GIP secretagogue. 
pri čemu sposobnost da test spoj stimulira GIP sekreciju iz enteroendokrine stanice kralježnjaka ili sposobnost stanice za GIP sekreciju, pokazuje da li je test spoj postao GIP sekretogog.
The view of atherosclerosis as a response to a damage of the endothelium was developed when the association of atherosclerosis with risk factors (high LDL plasma levels, low HDL plasma levels, hypertension, oxidative stress, tobacco consumption, diabetes mellitus, high Lp(a) plasma levels or modification of LDL such as oxidation or glycation that prevent LDL removal by the specific receptors) was studied. 
Gledanje ateroskleroze kao reakcije na ozljedu endotela bilo je razvijeno kad se je proučavalo povezanost ateroskleroze s faktorima rizika (visoka razina LDL u plazmi, niska razine HDL u plazmi, hipertenzija, oksidativan stres, pušenje, dijabetes melitus, visoka razina Lp(a) u plazmi ili modifikacija LDL kao što je oksidacija ili glikacija koja sprečava odstranjivanje LDL pomoću specifičnih receptora).
The construct for the use of claim 9 or 10, wherein the method is prior to allogeneic stem cell transplantation (HSCT) to convert the MRD positive ALL into an MRD negative status. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se postupak provodi prije alogenog presađivanja matičnih stanica (HSCT) kako bi se promijenilo ALI, pozitivnu na MRD u status negativnosti na MRD.
The CDR regions has been deleted for clarity. 
CDR ragije su izbrisane radi jasnoće,
The pharmaceutical composition of any one of claims 2 to 8, wherein the pharmaceutical composition is to be administered intravenously in an amount ranging from 1 µg compound of formula (1)/kg/minute to 100 µg compound of formula (1)/kg/minute. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu kao što je definirano u bilo kojem od patentnih zahtjeva 9-11, gdje spoj ili farmaceutska kompozicija se trebaju administrirati intravenski u količini koja je u opsegu od 10 µg spoja sa formulama (1) ili (2)/kg/minuti do 50 µg spoja sa formulama (1) ili (2)/kg/minuti.
The pharmaceutical composition as claimed in claim 10 wherein the HIV associated lipodystrophy causes lipohypertrophy or lipoatrophy or metabolic abnormality. 
Farmaceutski pripravak prema zahtjevu 10 gdje s HIV-om povezana lipodistrofija uzrokuje lipohipertrofiju ili lipoatrofiju ili metabolički poremećaj.
The method of claim 1, wherein the frozen G-CSF composition in step (c) is stored over a period of at least three months. 
Postupak prema bilo kojem zahtjevu od 1 do 7, naznačen time, da se zamrznuti G-CSF-sastav u koraku (c) pohranjuje u vremenskom periodu od najmanje tri mjeseca.
polynucleotide sequences encoding a polypeptide having at least 75% identity to SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10 or SEQ ID NO 12 or variants, homologues, fragments or derivatives thereof; 
polinukleotidnih sekvenci koje kodiraju polipeptid koji je najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10 ili SEQ ID NO 12 ili njihovim varijantama, homolozima, fragmentima ili derivatima i njihovim kombinacijama;
binding the eluted furin polypeptide or furin polypeptide derivative to an Arginine-Sepharose resin, and 
(C) Vezivanje navedenog furin polipeptida ili skraćenog furin polipeptida na Arginin- Sepharose smolu i
Compound of formula (I) according to claim 1, wherein R1 represents a linear or branched (C1-C6)alkyl group or a halogen atom. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R1 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu ili atom halogena.
The extracts were washed with a saturated aqueous solution of sodium chloride, dried and evaporated to give crude product. Purification by chromatography on silica gel eluting with a mixture of ethyl dichloromethane/methanol in the proportions 100/0 to 90/10 led to compound in the form of free base. 
Ekstrakte se ispere zasićenom vodenom otopinom natrijevog klorida, osuši, te otpari kako bi se dobilo sirovi produkt, Pročišćavanje kromatografijom na silikagelu, uz eluiranje smjesom etildiklormetan/metanol, u odnosima od 100/0 do 90/10, daje spoj u obliku slobodne baze.
all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; 
(i) sve operacije su provedene na sobnoj temperaturi ili temperaturi okoline, što je raspon 18-25" C;
Cyclopropyl substituted with one group selected from: -C(O)NH2, 
ciklopropil supstituiran s jednom skupinom odabranom od sljedećih:
In another aspect of the embodiment, the heterologous polynucleotide encoding an NDV-F antigen or polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 4, 6, 33, 35, or 37. In yet another aspect of the embodiment, the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1, 3, 5, 32, 34, or 36. 
Sastav ili cjepivo za uporabu prema zahtjevu 2, naznačen/o time, da rekombinantni vektor HVT je vHVT13. Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da sekvenca proteina NDV-F ima najmanje 90% identiteta sekvence prema sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54. Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da polinukleotid koji kodira NDV-F ima najmanje 90% identiteta sekvence prema SEQ ID NO: 1, 8, 49, 51 ili 53.
The procedure according to Examples 6 to 10 was used except that 1-tert-butoxycarbonylpiperazine was used as the amine and that after the aqueous work-up, the residue was stirred for 90 minutes in a 1:1 mixture of dichloromethane-trifluoroacetic acid (3 ml) and then purified by HPLC. 
Korišten je postupak u skladu sa Primjerima 6-10, uz tu razliku da je kao amin korišten 1 -terc-butoksikarbonilpiperazin i da je nakon vodene obrade talog miješan tijekom 90 minuta u 1:1 smjesi dikormetana:trifluoroctene kiseline (3 ml) i potom pročišćen HPLC-om.
further comprises an effector moiety that is a detectable moiety or a functional moiety, wherein said detectable moiety is optionally a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material and said functional moiety optionally is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material. 
dodatno sadrži efektorski ostatak koji je detektibilni ostatak ili funkcionalni ostatak, gdje navedeni detektibilni ostatak može biti fluorescentno bojilo, enzim, supstrat, bioluminescentni materijal, radioaktivni materijal, ili kemiluminescentni materijal, navedeni funkcionalni ostatak može biti streptavidin, avidin, biotin, citotoksin, citotoksično sredstvo, ili radioaktivni materijal.
The pharmaceutical composition of clause 7 or clause 8, wherein the salt is montelukast sodium and the corresponding sulfoxide is the sulfoxide of formula (I): 
Farmaceutska kompozicija prema patentnom zahtjevu 7 ili &, naznačena time što je sol montelukast natrij 1 odgovarajući sulfoksid je sulfoksid formule (1):
The molecule of claim 25, wherein the activated B chain has a conformation of B chain obtained by cleavage of single chain HGF. 
Molekula prema zahtjevu 25, naznačena time, da aktivirani B lanac ima konformaciju f lanca dobivenog cijepanjem jednolančanog HGF.
The formulation of paragraph 1 wherein the buffering agent is selected from the group consisting of citrate, glycine, histidine, HEPES, Tris and combinations of these agents. 
Formulacija prema zahtjevu 1, naznačena time da je pufer izabran iz grupe koju čine citrat, glicin, histidin, HEPES, tris i kombinacije ovih sredstava.
An adhesive composition according to claim 5, wherein the chain-extending reagent (ii) is a polyester polyol obtainable by polymerisation of a lactone such as a caprolactone selected from Y-caprolactone, δ-caprolactone, e-caprolactone, and preferably e-caprolactone. 
Sastav ljepila prema zahtjevu 5, naznačen time, da reagens produljivanja lanca (ii) je poliester-poliol koji se može dobiti pomoću polimerizacije laktona kao što je primjerice kaprolakton odabran od Y-kaprolaktona, δ-kaprolaktona, e-kaprolaktona, dok je poželjno odabran od e-kaprolaktona.
The fusion protein according to claim 1, wherein said first amino acid sequence has at least 95, 96, 97, 98 or 99 % sequence identity with an amino acid sequence as shown in SEQ ID NO:2 or wherein said second amino acid sequence have at least 95, 96, 97, 98 or 99 % sequence identity with an amino acid sequence as shown in SEQ ID NO:4. 
Fuzijski protein u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:2 ili pri čemu navedeni drugi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:4.
The method of claim 2, wherein the message is a signaling message from the primary station. 
Metoda iz patentnog zahtjeva 1, gdje je poruka (250) signalizirajuća poruka iz primarne stanice (100).
A composition for use in treating a human having fragile X syndrome, wherein the composition includes a therapeutically effective amount of at least one gamma-aminobutyric acid agonist. 
Pripravak namijenjen upotrebi u liječenju osobe sa sindromom lomljivog kromosoma X, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista Y-aminomaslačne kiseline.
The nonwoven fabric according to claim 1, wherein the unbonded portions are contiguous with one another in the nonwoven fabric. 
Netkani materijal prema zahtjevu 1, naznačen time da su nespojeni dijelovi susjedni jedan drugom u netkanom materijalu.
in an alcohol, more preferably an alcohol selected from the group consisting of methanol, ethanol and isopropanol; or 
Postupak prema zahtjevu 23, naznačen time da je alkohol odabran iz skupine koja se sastoji od metanola, etanola i izopropanola.
Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, e.g., to a simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as radioimmunoassay or ELISA assay. 
Stoga, za svaki je mutein moguće utvrditi ima li sadržajno istu aktivnost kao i IL-18BP, rutinskim pokusom podvrgavajući takav mutein pr. jednostavnom određivanju kompeticije u sendviču da bi se utvrdilo veže li se na odgovarajuće označen IL-18, poput radioimunoeseja i ELISA testa.
The apparatus according to any one of the preceding claims, wherein the control device is adapted to be implanted in the body of the patient. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
condensing the expanded DPFs into a cell aggregate that exhibit the size and shape of the physiological DP, wherein said DPFs are differentiated in non-adhesive culture vessels in a cell concentration per vessel surface of 1.000 to 100.000 DPFs/cm2, and 
(d) kondenziranja ekspandiranih DPF-ova u stanične agregate koji iskazuju veličinu 1 oblik fiziološke DP, pri čemu su navedeni DPF-ovi diferencirani u ne-adhezivnim posudama sa kulturom u staničnoj koncentraciji na površini posude od 1.000 do 100.000 DPF/cm', te
The antisense oligomer according to claim 8, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified, or a pharmaceutically acceptable salt or hydrate thereof. 
Suprotni oligomer u skladu s patentnim zahtjevom 2, naznačen time što šećerna skupina i/ili područje vezano fosfatom najmanje jednog nukleotida koji čini oligonukleotid je modificirano, ili njegova farmaceutski prihvatljiva sol ili hidrat.
administering a compound in the presence of which less of said complex is formed in step (c) to a mammal; and 
(c) određivanje da li se manje navedenog kompleksa formira u prisutnosti test spoja nego li u odsutnosti test spoja; pri čemu je navedeno određivanje indikativno da je test spoj GLP-1 sekretogog;
• oxidation of sulphides to sulphoxides or sulphones 
oksidacija sulfida do sulfoksida 1li sulfona
Plunger 42 can be moved with handle 43. 
Klipnjača 42 se može pomicati pomoću ručke 43.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereoisomeric mixture (R,S+S,S) 
I) reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehida formule dq s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+8, S) on EA Ubit SS
FIGURE 8 is a perspective view of a container matted with the tool of Figure 7 for spot welding according to the invention; 
SLIKA 8 je pogled u perspektivi na spremnik koji je načinjen s alatom iz slike 7 za točkasto zavarivanje u skladu s ovim izumom;